GlassScriptPhysician profile
Rahul Prakash
NPI 1902846108
$6,608.67
in general payments reported to CMS, 2019-2025
27 companies · $1,218 in 2025
The $1,218 reported for 2025 was more than what 82% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $718 · 2020: $669 · 2021: $1,094 · 2022: $585 · 2023: $1,019 · 2024: $1,306 · 2025: $1,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,485 · Education: $31.88 · Travel and Lodging: $25.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,485.18 |
| Education | $31.88 |
| Travel and Lodging | $25.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,112.87 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $561.19 | 2019-2025 | Jynarque |
| Horizon Therapeutics Plc | $556.51 | 2020-2023 | Krystexxa |
| Opko Pharmaceuticals, LLC | $465.59 | 2019-2024 | Rayaldee |
| Vifor Pharma, INC. | $458.09 | 2019-2025 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $438.77 | 2021-2025 | |
| Amgen INC. | $384.37 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Calliditas Therapeutics US INC. | $327.88 | 2022-2025 | Tarpeyo |
| Medtronic, INC. | $327.46 | 2023 | Ellipsys Vascular Access System |
| Travere Therapeutics, INC. | $282.65 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $244.08 | 2023-2025 | |
| Baxter Healthcare | $235.36 | 2019-2020 | |
| Glaxosmithkline, LLC. | $224.80 | 2020-2024 | Benlysta |
| Mallinckrodt Hospital Products INC. | $212.12 | 2023-2025 | Acthar, Terlivaz |
| Lilly USA, LLC | $161.36 | 2024-2025 | Jardiance |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $131.55 | 2021-2024 | Lupkynis |
| Akebia Therapeutics INC | $124.75 | 2019-2021 | |
| Ardelyx, INC. | $79.64 | 2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $65.78 | 2019-2025 | Gattex |
| Ultragenyx Pharmaceutical INC. | $56.79 | 2020-2021 | |
| Ani Pharmaceuticals, INC. | $36.83 | 2025 | Purified Cortrophin Gel |
| Recor Medical INC | $27.22 | 2025 | Paradise Ultrasound Renal Denervation System |
| Scpharmaceuticals INC. | $21.18 | 2025 | |
| Genzyme Corporation | $21.17 | 2021 | |
| Janssen Pharmaceuticals, INC | $19.23 | 2021 | |
| Fresenius USA Marketing, INC. | $17.16 | 2021 | |
| Novo Nordisk INC | $14.27 | 2024 | Ozempic, Rybelsus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahul Prakash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.